SCHEMBL2118766

SCHEMBL2118766

Cc1ccc(S(=O)(=O)Nc2cc(C)cc(-c3ccc(C#N)s3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
TP53 P04637 1/20 0.45
HSD17B1 P14061 3/20 0.45
HSD11B1 P28845 2/20 0.45
FFAR4 Q5NUL3 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
ALDH1A1 P00352 6/20 0.44
HTT P42858 3/20 0.43
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 3/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42
RORC P51449 1/20 0.42
HSD17B2 P37059 2/20 0.42
MEN1 O00255 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120005 0.92 FFAR4 (0.48) MAPTTP53HSD11B1FFAR4ALDH1A1
SCHEMBL2117531 0.90 FFAR4 (0.50) MAPTFFAR4ALDH1A1LMNAGAA
SCHEMBL2119599 0.84 DRD2 (0.53) MAPTTP53HSD17B1FFAR4CA12
SCHEMBL29498140 0.81 CYP2C9 (0.47) MAPTTP53HSD17B1HSD11B1FFAR4
SCHEMBL2118331 0.78 HSD11B1 (0.62) MAPTTP53HSD11B1KMT2A
SCHEMBL2119549 0.76 MAPT (0.46) MAPTTP53HSD11B1FFAR4CA12
SCHEMBL18870862 0.76 FFAR4 (0.67) MAPTTP53FFAR4CA12CA1
SCHEMBL2120312 0.75 HTT (0.59) MAPTTP53FFAR4CA12CA1
SCHEMBL2119740 0.75 FFAR4 (0.48) MAPTTP53HSD11B1FFAR4CA12
SCHEMBL2118403 0.74 FFAR4 (0.54) MAPTTP53FFAR4ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 MAPT 4523/4885TP53 193/4885HSD17B1 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.